Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with Enterobacterales Bacteremia. Huang HY, Wang CF, Lu PL, Tseng SP, et al. Antimicrob Agents Chemother 2021;65.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Huang HY, Wang CF, Lu PL, Tseng SP, et al. Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with Enterobacterales Bacteremia. Antimicrob Agents Chemother 2021;65.
PMID: 33782006